In March 2025, Coordination Pharmaceuticals Inc. announced a phase 1b/2a Study of RiMO-301 and Hypofractionated Radiotherapy With A PD-1 Inhibitor for the Treatment of Unresectable, Recurrent or ...

In April 2025, Amgen announced a study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose ...

Dr Kathleen Moore emphasizes the need for a more nuanced approach to endometrial cancer treatment, particularly in the ...

For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that GSK plc (NYSE: GSK) Misled ...

TIGIT in particular has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months ...

NEW YORK CITY, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

The Gross Law Firm issues the following notice to shareholders of GSK plc . Shareholders who purchased shares of GSK during the ...

Mirvetuximab soravtansine improved overall survival, progression-free survival, second progression-free survival, and other outcomes.

Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

When I’ve made mistakes on people, it’s usually for cultural reasons,” Walmsley told Norges Bank Investment Management CEO ...

GSK’s share price has fallen a long way from its one-year high, which has only increased the major undervaluation I'd seen in ...